Trial · NCT06926933
Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
NCT06926933, Phase 4, Active not recruiting, HanAll BioPharma Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty. Trials, record NCT06926933. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06926933
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy and Safety of Leuprolide Acetate 45 mg in Subjects With Central Precocious Puberty
- NCT number
- NCT06926933
- Status
- Active not recruiting
- Phases
- Phase 4
- Enrollment
- 50 participants, estimated
- Lead sponsor
- HanAll BioPharma Co., Ltd.
- Conditions
- CPP
- Interventions
- Eligard® 45 mg
- First posted
- 2025-04-15
- Last updated
- 2026-07-08
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The percentage (%) of subjects with serum LH concentrations < 4 IU/L following an GnRH stimulation test | at week 24 | Blood samples for serum LH concentrations (as appropriate) will be collected at the appropriate assessment times and analyzed by a central laboratory. |
| Secondary | The percentage (%) of subjects with suppressed serum LH concentrations (< 4 IU/L) 30-minutes post GnRH stimulation test | at week 12, 48, 72, 96 | Blood samples for serum LH concentrations (as appropriate) will be collected at the appropriate assessment times and analyzed by a central laboratory. |
| Secondary | The percentage (%) of subjects with suppressed serum FSH (< 2.5 mIU/mL), estradiol (< 20 pg/mL, for girl) or testosterone (< 30 ng/dL, for boy) | at week 12, 24, 48, 72, 96 | Sexual development in puberty will be assessed by Tanner staging |
| Secondary | The percentage of subject of Tanner stage (including menstruation) | at week 12, 24, 48, 72, 96 | Sexual development in puberty will be assessed by Tanner staging |
| Secondary | Height velocity (growth rate) | at week 12, 24, 48, 72, 96 | Annualized Height Velocity |
| Secondary | The ratio of bone age and chronological age | at week 12, 24, 48, 72, 96 | A single X-ray of the non-dominant hand and wrist will be obtained periodically |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06926933
GET https://conductscience.org/api/trials/v1/NCT06926933/registered